Latest Period
Q1 2026
Security Snapshot
BICYCLE THERAPEUTICS PLC - American Depositary Shares, each representing one ordinary share, nominal value 0.01 euro per share (BCYC) Institutional Ownership
CUSIP: 088786108
13F Institutional Holders and Ownership History from Q2 2019 to Q1 2026
Institutions Reporting
97
Shares (Excl. Options)
37,459,664
Price
$4.64
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / American Depositary Shares, each representing one ordinary share, nominal value 0.01 euro per share
- Symbol
- BCYC on Nasdaq
- Shares outstanding
- 50,340,741
- Price per share
- $4.73
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 37,459,664
- Total reported value
- $173,586,582
- % of total 13F portfolios
- 0%
- Share change
- -1,713,415
- Value change
- -$22,803,169
- Number of holders
- 97
- Price from insider filings
- $4.73
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- BCYC - BICYCLE THERAPEUTICS PLC - American Depositary Shares, each representing one ordinary share, nominal value 0.01 euro per share is tracked under CUSIP 088786108.
- 97 institutions reported positions in Q1 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 108 to 97 between Q4 2025 and Q1 2026.
- Reported value moved from $277,661,671 to $173,586,582.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 97 institutions filings for Q1 2026.
Security key
088786108
Latest holder period
Q1 2026
13F holders
97
13D/G owners
6
CIK / CUSIP context first
Open Q1 2026 holders
BCYC full holder history
BICYCLE THERAPEUTICS PLC SEC filings
BICYCLE THERAPEUTICS PLC company facts
BICYCLE THERAPEUTICS PLC insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 088786108:
Significant Owners of BICYCLE THERAPEUTICS PLC - American Depositary Shares, each representing one ordinary share, nominal value 0.01 euro per share (BCYC) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Forbion Growth Opportunities Fund II Cooperatief U.A. | 7.3% | $28,343,629 | 3,452,330 | Forbion Growth Opportunities Fund II Cooperatief U.A. | 21 Nov 2024 | |||
| ARMISTICE CAPITAL, LLC | 6.8% | +4.5% | $16,922,040 | +$806,760 | 3,398,000 | +5% | Armistice Capital, LLC | 31 Mar 2026 |
| Long Focus Capital Management, LLC | 6.6% | $16,487,221 | 3,310,687 | LONG FOCUS CAPITAL MANAGEMENT, LLC | 31 Mar 2026 | |||
| Point72 Asset Management, L.P. | 3.9% | -49% | $14,882,536 | -$15,032,008 | 1,860,317 | -50% | Point72 Asset Management, L.P. | 30 Jun 2025 |
| Invus Global Management, LLC | 3.1% | -53% | $7,773,192 | -$7,909,072 | 1,560,882 | -50% | Raymond Debbane | 31 Mar 2026 |
| Deep Track Capital, LP | 2.4% | -54% | $9,625,952 | -$12,943,416 | 1,203,244 | -57% | Deep Track Capital, LP | 30 Jun 2025 |
As of 31 Mar 2026, 97 institutional investors reported holding 37,459,664 shares of BICYCLE THERAPEUTICS PLC - American Depositary Shares, each representing one ordinary share, nominal value 0.01 euro per share (BCYC). This represents 74% of the company’s total 50,340,741 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of BICYCLE THERAPEUTICS PLC - American Depositary Shares, each representing one ordinary share, nominal value 0.01 euro per share (BCYC) together control 69% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | 22% | 10,885,357 | 0% | 0.29% | $50,508,056 |
| FCPM III SERVICES B.V. | 6.9% | 3,468,430 | 0% | 2.2% | $16,093,515 |
| ARMISTICE CAPITAL, LLC | 6.7% | 3,398,000 | +5% | 0.52% | $15,766,720 |
| Long Focus Capital Management, LLC | 6.6% | 3,310,687 | +103% | 0.68% | $15,361,588 |
| ACADIAN ASSET MANAGEMENT LLC | 3.9% | 1,968,025 | +18% | 0.01% | $9,111,000 |
| Siren, L.L.C. | 3.1% | 1,560,882 | -22% | 0.2% | $7,242,492 |
| GSK plc | 3% | 1,529,561 | 0% | 1.2% | $7,097,163 |
| PRINCIPAL FINANCIAL GROUP INC | 2.3% | 1,174,625 | +2.3% | 0% | $5,450,260 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2% | 1,028,243 | -12% | 0% | $4,772,000 |
| RENAISSANCE TECHNOLOGIES LLC | 1.9% | 979,300 | +73% | 0.01% | $4,543,952 |
| MORGAN STANLEY | 1.2% | 618,327 | +33% | 0% | $2,869,038 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | 1.2% | 615,833 | +5.3% | 0% | $2,672,715 |
| DIADEMA PARTNERS LP | 0.95% | 476,424 | 0.99% | $2,210,607 | |
| Birchview Capital, LP | 0.92% | 463,599 | +0.19% | 1.2% | $2,151,099 |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | 0.85% | 428,684 | -10% | 0.01% | $1,989,094 |
| MARSHALL WACE, LLP | 0.75% | 377,335 | +873% | 0% | $1,750,834 |
| CITADEL ADVISORS LLC | 0.75% | 377,085 | +39% | 0% | $1,749,674 |
| Qube Research & Technologies Ltd | 0.61% | 308,617 | 0% | $1,431,983 | |
| MILLENNIUM MANAGEMENT LLC | 0.56% | 283,986 | -13% | 0% | $1,317,695 |
| BlackRock, Inc. | 0.55% | 278,992 | -16% | 0% | $1,294,523 |
| MOORE CAPITAL MANAGEMENT, LP | 0.55% | 275,000 | 0% | 0.05% | $1,276,000 |
| Rangeley Capital, LLC | 0.46% | 232,260 | +76% | 1.2% | $1,077,686 |
| JANE STREET GROUP, LLC | 0.43% | 218,115 | +245% | 0% | $1,012,053 |
| Palo Alto Investors LP | 0.4% | 201,890 | -8.7% | 0.14% | $936,770 |
| Eversept Partners, LP | 0.38% | 190,715 | +6.6% | 0.06% | $884,918 |
Institutional Holders of BICYCLE THERAPEUTICS PLC - American Depositary Shares, each representing one ordinary share, nominal value 0.01 euro per share (BCYC) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 37,459,664 | $173,586,582 | -$22,803,169 | $4.64 | 97 |
| 2025 Q4 | 39,173,179 | $277,661,671 | +$3,442,632 | $7.08 | 108 |
| 2025 Q3 | 36,906,185 | $285,619,779 | -$29,768,237 | $7.74 | 99 |
| 2025 Q2 | 41,200,406 | $286,338,478 | -$7,404,258 | $6.95 | 110 |
| 2025 Q1 | 41,735,285 | $354,350,748 | -$8,366,393 | $8.49 | 95 |
| 2024 Q4 | 41,890,221 | $586,472,317 | -$21,543,705 | $14.00 | 96 |
| 2024 Q3 | 40,439,351 | $915,266,321 | +$21,080,974 | $22.63 | 104 |
| 2024 Q2 | 39,722,044 | $803,959,492 | +$167,237,644 | $20.24 | 105 |
| 2024 Q1 | 30,475,266 | $758,677,656 | +$6,974,793 | $24.90 | 93 |
| 2023 Q4 | 31,374,408 | $567,252,558 | -$28,664,876 | $18.08 | 98 |
| 2023 Q3 | 32,418,922 | $651,281,538 | +$165,201,151 | $20.09 | 101 |
| 2023 Q2 | 24,236,173 | $618,449,426 | +$18,484,148 | $25.52 | 84 |
| 2023 Q1 | 23,558,818 | $498,895,905 | -$47,151,037 | $21.27 | 89 |
| 2022 Q4 | 23,577,228 | $697,847,861 | +$39,624,167 | $29.60 | 87 |
| 2022 Q3 | 23,196,999 | $539,598,338 | +$13,911,506 | $23.26 | 77 |
| 2022 Q2 | 22,709,672 | $381,075,755 | -$69,885,312 | $16.78 | 78 |
| 2022 Q1 | 20,168,148 | $884,247,452 | -$137,175,184 | $43.88 | 100 |
| 2021 Q4 | 21,550,279 | $1,311,636,981 | +$387,558,387 | $60.87 | 98 |
| 2021 Q3 | 14,210,499 | $591,072,741 | +$80,484,868 | $41.59 | 67 |
| 2021 Q2 | 12,412,613 | $376,901,461 | +$30,169,498 | $30.36 | 53 |
| 2021 Q1 | 11,420,830 | $341,203,000 | +$123,064,104 | $29.87 | 39 |
| 2020 Q4 | 7,328,435 | $131,544,000 | -$3,975,466 | $17.95 | 27 |
| 2020 Q3 | 7,550,163 | $143,830,000 | +$24,085,212 | $19.05 | 18 |
| 2020 Q2 | 6,287,737 | $98,861,000 | +$4,298,929 | $15.74 | 15 |
| 2020 Q1 | 5,977,254 | $81,901,000 | +$1,078,206 | $13.65 | 12 |
| 2019 Q4 | 5,901,993 | $55,657,000 | -$6,870,216 | $9.43 | 8 |
| 2019 Q3 | 6,446,149 | $73,420,000 | -$1,907,302 | $11.39 | 11 |
| 2019 Q2 | 6,635,216 | $66,751,000 | +$66,751,000 | $10.06 | 14 |